• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[两步超剂量化疗联合外周血干细胞自体移植治疗难治性睾丸癌:一例报告]

[Two-step ultra high-dose chemotherapy with peripheral blood stem cell autotransplantation for refractory testicular cancer: a case report].

作者信息

Maeda N, Yoshida T, Sonoda T, Kanayama Y, Cho S, Nishizaki S

机构信息

Department of Urology, Ashiya Municipal Hospital.

出版信息

Hinyokika Kiyo. 1999 Jun;45(6):447-50.

PMID:10442292
Abstract

A 35-year-old male had advanced nonseminomatous germ cell tumor (stage IIIC, embryonal cell carcinoma) which proved refractory to conventional PVB combined chemotherapy. He was then treated with an ultra high-dose chemotherapy consisting of carboplatin (1.5 g/m2) and etoposide (1.3 g/m2), followed by the transplantation of peripheral blood stem cells (PBSCT) with a total of 1.9 x 10(5)/kg granulocyte colony-forming cells (CFU-GM). Because he developed lung metastasis, escalated doses of carboplatin (2.0 g/m2), and etoposide (1.8 g/m2) combined with cyclophosphamide (7.0 g/m2) were given with peripheral blood stem cell transplant of 3.2 x 10(5)/kg CFU-GM. He has remained free of any recurrence without maintenance therapy.

摘要

一名35岁男性患有晚期非精原细胞性生殖细胞肿瘤(IIIC期,胚胎细胞癌),事实证明其对传统的顺铂-长春新碱-博来霉素联合化疗无效。随后他接受了由卡铂(1.5 g/m²)和依托泊苷(1.3 g/m²)组成的超高剂量化疗,接着进行了外周血干细胞移植(PBSCT),共移植1.9×10⁵/kg粒细胞集落形成细胞(CFU-GM)。由于他出现了肺转移,于是给予了递增剂量的卡铂(2.0 g/m²)、依托泊苷(1.8 g/m²)并联合环磷酰胺(7.0 g/m²),同时进行了3.2×10⁵/kg CFU-GM的外周血干细胞移植。他未经维持治疗,至今未出现任何复发情况。

相似文献

1
[Two-step ultra high-dose chemotherapy with peripheral blood stem cell autotransplantation for refractory testicular cancer: a case report].[两步超剂量化疗联合外周血干细胞自体移植治疗难治性睾丸癌:一例报告]
Hinyokika Kiyo. 1999 Jun;45(6):447-50.
2
[Ultra high-dose chemotherapy with peripheral blood stem cell autotransplantation for refractory testicular cancer].[超高剂量化疗联合外周血干细胞自体移植治疗难治性睾丸癌]
Hinyokika Kiyo. 1994 Feb;40(2):155-9.
3
Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.高剂量卡铂、依托泊苷和环磷酰胺联合自体骨髓移植治疗难治性生殖细胞肿瘤的Ⅰ期药代动力学分析试验。
Cancer Res. 1993 Aug 15;53(16):3730-5.
4
[Refractory germ cell cancer of testis treated by salvage high-dose chemotherapy: report of three cases].[挽救性高剂量化疗治疗难治性睾丸生殖细胞癌:三例报告]
Hinyokika Kiyo. 2004 Feb;50(2):77-80.
5
Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience.高剂量化疗(高剂量异环磷酰胺、卡铂和依托泊苷)联合外周血干细胞移植治疗男性生殖细胞肿瘤的可行性和实用性:单机构经验
Anticancer Drugs. 2006 Oct;17(9):1057-66. doi: 10.1097/01.cad.0000231469.46664.12.
6
[High-dose chemotherapy with autologous peripheral blood stem cell transfusion in the treatment of advanced testis cancer].
Gan To Kagaku Ryoho. 1998 Sep;25(11):1739-45.
7
[Clinical study of high-dose chemotherapy with peripheral blood stem cell transplantation for poor-risk germ cell tumor].高剂量化疗联合外周血干细胞移植治疗高危生殖细胞肿瘤的临床研究
Hinyokika Kiyo. 1999 Nov;45(11):793-8.
8
[High-dose chemotherapy with peripheral blood stem cell autotransplantation for patients with poor-risk testicular germ cell tumors--pilot study of the Japan Blood Cell Transplantation Study Group].[高剂量化疗联合外周血干细胞自体移植治疗高危睾丸生殖细胞肿瘤患者——日本血细胞移植研究组的初步研究]
Hinyokika Kiyo. 1999 Nov;45(11):805-9.
9
[High dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) For advanced testicular cancer].[高剂量化疗联合外周血干细胞移植治疗晚期睾丸癌]
Hinyokika Kiyo. 1998 May;44(5):313-8.
10
[A case of neutropenic enterocolitis in high dose chemotherapy with peripheral blood stem cell transplantation for relapsed testicular tumor].
Hinyokika Kiyo. 1998 Oct;44(10):743-5.